DRREDDY.NS - Dr. Reddy's Laboratories Limited
| Previous Close | 2,136.30 |
| Open | 2,130.00 |
| Bid | 0.00 x 0 |
| Ask | 2,121.90 x 0 |
| Day's Range | 2,106.05 - 2,145.95 |
| 52 Week Range | 1,901.15 - 2,787.00 |
| Volume | 267,336 |
| Avg. Volume | 548,423 |
| Market Cap | 351.412B |
| Beta | 0.14 |
| PE Ratio (TTM) | 35.57 |
| EPS (TTM) | 59.66 |
| Earnings Date | May 22, 2018 |
| Forward Dividend & Yield | 20.00 (0.95%) |
| Ex-Dividend Date | 2017-07-17 |
| 1y Target Est | 2,587.45 |
- Business Wire•19 days ago
Dr. Reddy's Laboratories and its U.S. subsidiary Promius Pharma announce the filing of an NDA for its migraine candidate
Dr. Reddy’s Laboratories Ltd and its subsidiary, Promius Pharma, LLC today announced the filing of New Drug Application for its migraine candidate DFN-02 with the U.S.
- Business Wire•23 days ago
Dr. Reddy's Laboratories Announces Senior Leadership Changes
Dr. Reddy’s Laboratories Ltd. today announced a change in the makeup of its senior leadership team.
- Simply Wall St.•25 days ago
Dr Reddy’s Laboratories Limited (NSE:DRREDDY): Time For A Financial Health Check
Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like Dr Reddy’s Laboratories Limited (NSEI:DRREDDY), with a market cap of ₹348.85B, are often out ofRead More...
- Business Wire•26 days ago
Dr. Reddy's Laboratories Announces the Launch of Palonosetron Hydrochloride Injection in the U.S. Market
Dr. Reddy’s Laboratories Ltd. announced today that it has launched Palonosetron Hydrochloride Injection, 0.25 mg / 5 mL, a therapeutic equivalent generic version of ALOXI® Injection approved by the U.S.
- Business Wire•last month
Dr. Reddy's Laboratories Announces the Launch of Levocetirizine Dihydrochloride Tablets USP, 5 mg in the U.S. Market
Dr. Reddy’s Laboratories Ltd announced today that it has launched Levocetirizine Dihydrochloride Tablets USP, 5 mg, an over-the-counter therapeutic equivalent generic version of Xyzal® Allergy 24HR Tablets in the United States market as approved by the U.S.
- Zacks•last month
Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals
Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals
- Simply Wall St.•2 months ago
Does Dr Reddy’s Laboratories Limited’s (NSE:DRREDDY) PE Ratio Warrant A Sell?
Dr Reddy’s Laboratories Limited (NSEI:DRREDDY) is currently trading at a trailing P/E of 36.5x, which is higher than the industry average of 29.5x. While this makes DRREDDY appear like aRead More...
- Business Wire•3 months ago
Dr. Reddy's Laboratories Announces the Launch of Tetrabenazine Tablets in the U.S. Market
Dr. Reddy’s Laboratories Ltd announced today that it has launched Tetrabenazine Tablets, a therapeutic equivalent generic version of Xenazine® in the United States market approved by the U.S.
- Simply Wall St.•3 months ago
Will Dr Reddy’s Laboratories Limited (NSE:DRREDDY) Continue To Underperform Its Industry?
Dr Reddy’s Laboratories Limited (NSEI:DRREDDY) delivered a less impressive 9.50% ROE over the past year, compared to the 13.67% return generated by its industry. Though DRREDDY’s recent performance is underwhelming,Read More...
- Zacks•3 months ago
Dr. Reddy's (RDY) Q3 Earnings Fall, Revenues Improve Y/Y
Dr. Reddy's (RDY) earnings per American Depositary Share were down 27.3% in third-quarter fiscal 2018 from the year-ago quarter while the top line beat the prior-year figure.
- Associated Press•3 months ago
Doctor Reddy's posts 3Q profit
The Hyderabad, India-based company said it had profit of 32 cents per share. Earnings, adjusted for pretax expenses, were 41 cents per share. The pharmaceutical posted revenue of $596 million in the period. ...
- Business Wire•3 months ago
Dr. Reddy’s Q3 and 9M FY18 Financial Results
Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the third quarter and nine months ended December 31, 2017 under International Financial Reporting Standards .
- Business Wire•3 months ago
Dr. Reddy's to release Q3 FY18 results on January 25, 2018
Dr. Reddy's Laboratories will announce results for the Third Quarter ended December 31, 2017 on Thursday, January 25, 2018 after the Board Meeting.
- Business Wire•3 months ago
Dr. Reddy's Laboratories Limited to Present at the 36th Annual J.P. Morgan Healthcare Conference
Dr. Reddy’s Laboratories Ltd announced that the Company will be presenting at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, California.
- Simply Wall St.•4 months ago
Dr Reddy’s Laboratories Limited’s (NSE:DRREDDY) Earnings Grew 6.9% In A Year. Was It Better Than Its Long-Term Trend?
Measuring Dr Reddy’s Laboratories Limited’s (NSEI:DRREDDY) track record of past performance is a useful exercise for investors. It enables us to understand whether or not the company has met orRead More...
- Business Wire•4 months ago
Dr. Reddy's Laboratories announces the launch of Melphalan Hydrochloride for Injection in the U.S. Market
Dr. Reddy’s Laboratories Ltd announced today that it has launched Melphalan Hydrochloride for Injection, a therapeutic equivalent generic version of Alkeran® for Injection in the United States market approved by the U.S.
- Simply Wall St.•4 months ago
How Do Analysts See Dr Reddy’s Laboratories Limited (NSE:DRREDDY) Performing Over The Couple Of Years?
The latest earnings release Dr Reddy’s Laboratories Limited’s (NSEI:DRREDDY) announced in September 2017 suggested that the company experienced a significant headwind with earnings deteriorating by -39.84%. Today I want toRead More...
- Business Wire•4 months ago
Dr. Reddy’s announces it has reached a settlement with the US Government regarding company’s compliance with the Consumer Product Safety Act
—The US subsidiary of Dr. Reddy’s Laboratories Ltd. announced today that it has reached a settlement with the US Government, in a case that is more than six years old, involving packaging for five blister-packed prescription products.
- Reuters•4 months ago
Dr. Reddy's resolves U.S. probe over child safety of drug packaging
The settlement was disclosed in documents filed in federal court in Trenton, New Jersey, over a year after the U.S. Consumer Product Safety Commission voted to refer a case involving the drugmaker to the U.S. Justice Department. Dr. Reddy's in a statement said that the safety of patients and consumers was of "paramount importance" to the company. It said it disagreed with the allegations but agreed to the settlement to avoid prolonged litigation.
- Reuters•4 months ago
Dr. Reddy's resolves U.S. probe over child safety of drug packaging
Dr. Reddy's Laboratories Ltd will pay $5 million to resolve U.S. claims that the Indian company sold prescription drugs in the United States in packaging that was not tested for child safety, according to court papers filed on Monday. The settlement was disclosed in documents filed in federal court in Trenton, New Jersey, over a year after the U.S. Consumer Product Safety Commission voted to refer a case involving the drugmaker to the U.S. Justice Department. Dr. Reddy's in a statement said that the safety of patients and consumers was of "paramount importance" to the company.
- Simply Wall St.•4 months ago
Is Dr Reddy’s Laboratories Limited (NSE:DRREDDY) A Financially Sound Company?
Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Dr Reddy’s Laboratories Limited (NSEI:DRREDDY) with a market-capitalization of ₹363.73B, rarely draw their attention and few analystsRead More...
- Business Wire•5 months ago
Dr. Reddy’s Announces Approval of Impoyz™ (clobetasol propionate) Cream, 0.025% First-Cycle NDA Approval
Dr. Reddy’s Laboratories Ltd. , through its wholly owned subsidiary Promius Pharma, LLC, today announced its fifth consecutive, first-cycle NDA approval for the Proprietary Products Group, a substantial milestone within the pharmaceutical industry.
- Reuters•5 months ago
Exclusive: Prescient messages about Indian companies circulate in WhatsApp groups
Three days before Dr. Reddy's Laboratories Ltd announced quarterly results this summer, a message circulated on a private WhatsApp group saying the Indian drugmaker would not post good numbers. Dr. Reddy's was going to report a loss, according to the message on the "Market Chatter" group, which was posted on July 24 from a mobile phone number that Reuters traced back to Nishant Vass, an auto analyst at ICICI Securities, a leading Indian brokerage. The WhatsApp group had 45 members, mostly traders.
- Reuters•5 months ago
Exclusive: Prescient messages about Indian companies circulate in WhatsApp groups
Three days before Dr. Reddy's Laboratories Ltd announced quarterly results this summer, a message circulated on a private WhatsApp group saying the Indian drugmaker would not post good numbers. Dr. Reddy's was going to report a loss, according to the message on the "Market Chatter" group, which was posted on July 24 from a mobile phone number that Reuters traced back to Nishant Vass, an auto analyst at ICICI Securities, a leading Indian brokerage. The WhatsApp group had 45 members, mostly traders.
- Business Wire•5 months ago
Dr. Reddy's Laboratories Announces the Launch of Clofarabine Injection in the U.S. Market
Dr. Reddy’s Laboratories Ltd announced today that it has launched Clofarabine Injection, a therapeutic equivalent generic version of Clolar® Injection in the United States market, approved by the U.S.
